Trelleborg: A Long-Term Owner's Perspective

On industry attractiveness, my judgment is not "a monopoly leader in a great industry" but an excellent company clearly above average within a moderately attractive industrial niche. Long-term industry demand is stable but not entirely decoupled from the cycle; technological-substitution risk exists, but the bigger risk is usually not "being suddenly wiped out by new technology" but rather customer budgets, end-market output, M&A integration, and regional competition. If the stock market closed for 5 years, I would be willing to hold this business; but only on the condition that the entry price is not too aggressive. Business comprehensibility score: 4/5. Industry attractiveness score: 3.5/5.

Moat and Management

Breaking the moat down element by element, Trelleborg's most valuable asset is neither a consumer brand nor a network effect, but applied engineering capability, validation/switching costs, a globally localized manufacturing and sales network, and an ongoing ability to optimize the portfolio. The table below is more useful than simply saying "it has a moat":

Is the moat widening, stable, or narrowing? My judgment is: broadly stable, with the niche structure improving, but not yet clearly "widening." The evidence of improvement is that the company has already sold off more cyclical, lower-quality assets such as tires and printing blankets, and has steadily redirected resources toward better areas like medical, aerospace, semiconductors, and water infrastructure; in 2025 the EBITA margin reached 18.3%, a full-year record high. The reason it is not yet "clearly widening" is that the group's ROCE (excluding comparison items) is only 12.1%-12.3%, still below the company's own target of >15% over the economic cycle. The direction of the portfolio upgrade is right, but new investment and new acquisitions have not yet fully translated into higher returns on capital.

Does it have pricing power? I would say cautiously: some pricing power, but not unlimited pricing power. In Q4 2025 the company stated explicitly that, faced with unavoidable tariffs, its starting point is to offset rising costs through price increases; meanwhile, even after a negative currency impact of SEK 329m in 2025, the full-year EBITA margin still set a record. This looks more like "a high-quality industrial able to pass through part of its costs" than "a pure price-taker."

Can it stay profitable in a downturn? The historical data answers most likely yes. In 2020, continuing-operations sales were SEK 21,494m, with EBIT (excluding comparison items) still at SEK 3,006m, free cash flow of SEK 3,916m, and cash conversion of 128%. This does not guarantee a future recession would be so easy, but it at least shows this is not a company that "earns a lot when conditions are good and sees cash flow collapse the moment conditions turn."

On management, my view is moderately positive. Four things stand out in its capital allocation. First, portfolio reshaping: the 2023 divestment of the tire and printing-blanket businesses produced an after-tax capital gain of SEK 6,052m, which in essence swapped lower-quality, more cyclical assets for a more focused, higher-value portfolio. Second, bolt-on M&A style: the 2025 disclosed acquisitions, such as CRC Distribution, Aero-Plastics, Sico, and Masterseals, were mostly modest in size, with 2024 sales largely in the SEK 40m-280m range, and the company explicitly expects their impact on key group metrics to be only "marginal." Third, clear shareholder returns: for 2025 the board proposed a dividend of SEK 8.00/share, up from 7.50 the prior year, and the stated purpose of buybacks is explicitly "to optimize the capital structure and increase shareholder value," paired with cancellation. Fourth, a clear order of cash priorities: small bolt-on acquisitions and capacity investment first, then a stable dividend, then buybacks to adjust the capital structure.

But it cannot be praised unconditionally. Within management incentives, the CEO's annual variable pay is driven mainly by EBT (65%), operating cash flow (25%), and sustainability (10%); the long-term incentive plan is centered on EPS, and requires executives to hold shares above a certain multiple of base salary, with the CEO required to hold 100% of fixed annual salary. This reflects a long-term orientation, but it also means per-share metrics matter a great deal in the culture, so investors must keep watching closely: whether buybacks are done when shares are undervalued or overused when overvalued; and whether acquisitions are creating per-share intrinsic value or merely expanding scale and "padding EPS."

On balance, I believe management is broadly trustworthy and the direction of capital allocation is generally rational, but I would stay cautious about "when ROCE will recover meaningfully after the acquisitions." Moat strength score: 3.5/5. Management and capital allocation score: 4/5.

Financial Quality and Owner Earnings

First, the most important fact: 2025 was a record year for margins, but not a record year for return on capital. Full-year sales were SEK 34,329m, EBITA (excluding comparison items) was SEK 6,286m at a 18.3% margin, operating cash flow was SEK 5,288m, and free cash flow was SEK 3,351m; at the same time, ROCE (excluding comparison items) was only 12.1%, still below the company's long-term target of >15%. On a trailing-12-month basis through Q1 2026, sales were SEK 34,069m, EBITA (excluding comparison items) was SEK 6,256m, operating cash flow was SEK 5,404m, and net debt/EBITDA was 1.1x, with the overall picture still very sturdy.

Key Financial Metrics Table

• Rolled up / extrapolated from the company's disclosed quarterly data. ** The 2023 figure here uses continuing-operations net profit; on a group basis, total 2023 net profit rose to SEK 10,074m owing to the one-off gain on asset disposals, and cannot be used directly for normalized valuation. The table above is compiled from the company's 2023 ten-year overview, 2025 annual/year-end report, Q1 2026 report, and the official debt page.

This table makes four very important points.

First, revenue growth is broadly real, but the growth is not effortless. From 2021 to 2025, sales rose from SEK 23.8bn to SEK 34.3bn, driven jointly by portfolio optimization, pricing/product mix, acquisitions, and some organic growth. In Q1 2026 sales fell 3% year over year, but organic growth was still 4%, showing that short-term reported swings contain clear currency noise.

Second, margins are impressive, but return on capital has not yet caught up to the higher margins. In 2025 the EBITA margin rose to 18.3%, the best on record; yet ROCE still hovers around 12%. Medical Solutions in particular, despite a 2025 EBITA margin as high as 20.8%, had a return on capital of only 5.1%, indicating that new acquisitions and newly built capacity are still in a digestion phase. One cannot look at margins alone and rashly conclude "the company keeps getting better."

Third, cash-flow quality is very good. Operating cash flow was SEK 5,063m, 5,011m, and 5,288m in 2023, 2024, and 2025 respectively; free cash flow was SEK 2,526m, 2,917m, and 3,351m respectively. The 2025 cash conversion rate was 93%, rising further to 95% on a trailing-12-month basis in Q1 2026. This is a company where "profit broadly lands as cash," not one that dresses up earnings through accounting line items.

Fourth, the balance sheet is conservative. At year-end 2025, net debt was SEK 7,216m and net debt/EBITDA was 1.0x; at the end of Q1 2026, net debt was SEK 7,800m and net debt/EBITDA was 1.1x. The company's official debt page also shows an EBITDA/net-interest multiple of 15.0x for 2025. By capital structure, it is in no way aggressive. In 2022, leverage rose temporarily to 2.5x owing to a large acquisition, but it was repaired quickly afterward, which also reflects genuinely strong cash generation.

On working capital, inventory, receivables, and payables, I must clearly separate "confirmed" from "unconfirmed" here. The confirmed facts are: the company's working capital consumed cash of SEK 1,125m, 352m, and 500m in 2023, 2024, and 2025 respectively, and about SEK 416m on a trailing-12-month basis in Q1 2026, with no sign of going out of control. The unconfirmed part is: because the official pages retrievable this time do not fully expand the year-by-year inventory/receivables/payables detail for the past 5-10 years, I am unwilling to hard-code specific turnover days. If you intend to make a final position decision, I recommend re-checking the original tables in the official annual report or the company's key-figures Excel.

The share-count changes and shareholder returns are very clear. Total share capital fell from 255.1m at year-end 2023 to 231.3m at year-end 2025, and further to 224.9m in April 2026; in 2025 the company spent SEK 2,658m of cash buying back its own shares, with another SEK 500m repurchased in Q1 2026. The dividend rose from SEK 5.00/share in 2021 to the SEK 8.00/share proposed by the board for 2025. This shows management has executed consistently on "repurchasing and cancelling shares plus a progressive dividend."

On accounting risk, I see no strong signal of financial fraud or extremely aggressive accounting. What truly warrants caution is not "revenue conjured out of thin air" but two things: first, goodwill and intangible assets added by acquisitions will blunt ROCE; second, the 2023 asset-disposal gain will completely distort unadjusted EPS/P/E. So anyone who takes 2023 group net profit directly into a valuation will most likely reach a conclusion detached from reality.

Owner Earnings Analysis

In a Buffett-style analysis, what I care about most is not "what accounting profit looks like" but how much cash an owner can actually take out of this business in a year without harming long-term competitiveness. Here I give a conservative estimate:

The maintenance capex above is an assumption, not a figure the company states explicitly; the reason I neither use total capex directly nor add back all intangible amortization is to keep the estimate on the conservative side. On this basis, Trelleborg's true distributable cash flow is broadly close to its free cash flow in recent years, indicating that FCF does not materially overstate the company's true earning power. This is very important: it means Trelleborg is not fabricating cash flow by "suppressing capex," nor inflating profit through one-off items.

If we estimate using the current equity value of about SEK 89 billion and conservative Owner Earnings of SEK 3.2-3.4 billion, the market is valuing it at roughly 26-28x Owner Earnings. For a high-quality industrial that is not outrageous, but for a conservative value investor, it is certainly not a price for "buying real cash flow at a big discount."

Intrinsic Value, Margin of Safety, and Opportunity Cost

Method One: Discounted Owner Earnings

The core assumptions I use are as follows: starting Owner Earnings of SEK 3.3bn; a discount rate built on the Swedish 10-year government bond yield of about 2.73% as the risk-free base, plus business-risk and single-stock risk premiums, set at 8.5% / 8.0% / 7.5%; and a terminal growth rate of 2.0% / 2.5% / 3.0%. The reason I do not go lower is that the current risk-free rate is not low, and Trelleborg is, after all, still a cyclical industrial, ill-suited to a "utility-style discount rate."

These valuations are not facts but model outputs based on the financial and Owner Earnings data above. They tell me one thing: today's price sits roughly between "neutral and slightly expensive" and "optimistic and just about acceptable." For a balanced, slightly conservative 10-year investor, that is not enough.

Method Two: Relative Valuation

Relative valuation can only serve as a "calibrator," not as the main decision-maker, but it is still useful. On the currently visible basis, Trelleborg sits roughly in this position:

The conclusion from relative valuation is direct: Trelleborg does deserve a higher valuation than the average Swedish industrial, but right now it is not cheap enough to let you ignore cycle and execution risk. In other words, it is more of a "quality-premium stock" than a "value-discount stock."

Method Three: Asset or Liquidation Value

On an asset basis, the conclusion is not friendly to value investors. At the end of Q1 2026, the company's net debt was SEK 7.8bn and the debt-to-equity ratio was 21%; working backward on this basis, book shareholders' equity is roughly SEK 37bn, while the current equity value across the full economic interest is about SEK 89bn. That means the market is paying roughly 2.4x book equity. This makes clear that your investment return depends mainly on compounding earnings and cash flow over the next 10 years, not on some cushion below net asset value.

Combining the three methods, I would offer the following set of price ranges:

At the current price of roughly SEK 398-400, Trelleborg sits roughly above the upper edge of fair value and below optimistic value. For a conservative investor, this means: it is not that you cannot buy, but that it is not worth rushing to buy. The margin of safety I want is at least 20%-30%, and I do not see it at present.

Margin of Safety and Opportunity Cost

Is the current price cheap enough? No. What is the most fragile assumption in the valuation? That acquisitions and capacity expansion can ultimately pull ROCE back closer to the company's target. If growth comes in below expectations, can returns still be reasonable? Yes, but most likely only low-to-mid single digits. If margins decline, does the investment still hold? The business still holds, but the rate of return is revised down clearly. If the valuation multiple contracts, could it cause permanent capital loss? Yes; because the starting point of buying at the current price is not low. Is this a "good company at a bad price"? It is close to that state. Is it worth waiting for a better price? Yes.

Using a very plain 10-year return framework, and assuming a current clean P/E of about 23x and a dividend yield of about 2%: In the conservative scenario, if profit grows only 3% over the long run and the exit multiple falls back to 18x, the annualized total return is only about 2%-4%; In the neutral scenario, if profit grows 5%-6% over the long run and the exit multiple is around 22x, the annualized return is roughly 6%-8%; In the optimistic scenario, if profit grows 7%-8% over the long run and the exit multiple can still hold around 25x, the annualized return could be 9%-11%. These are not bad returns, but given the burden of single-stock risk, M&A execution risk, and cycle risk, they are also not good enough to clearly beat a low-cost broad-based index.

The conclusion becomes even clearer compared with the risk-free yield: the Swedish 10-year government bond yield is currently about 2.73%, while Trelleborg's free-cash-flow yield at the current price is only about 4%. This still carries a risk premium, but it is far from "enormous compensation." So my stance is not bearish on the company, but that the price is not generous enough.

Risks, Checklist, and Final Conclusion

I rank the most important risks by the framework of "permanent capital loss," not by short-term volatility.

The first category is competitive and demand-structure risk. Trelleborg is not a monopolist, and customers do not depend on it alone. If Sealing Solutions' technology and delivery edge in industrial/automotive/aerospace weakens, or if Medical Solutions' new capacity and new acquisitions keep failing to translate into high returns, the basis for the high valuation will wobble. In particular, Medical Solutions' current 20.8% margin paired with 5.1% ROCE is itself a reminder to investors that the return on capital is not yet mature.

The second category is technology and portfolio-substitution risk. Although demand for sealing and engineered polymers will not suddenly disappear, customer material systems, product structures, automation solutions, and supply-chain regionalization will all change. If Trelleborg cannot keep pace with faster-growing niches such as aerospace, medical, semiconductors, and hydrogen, the so-called "high-quality portfolio upgrade" could stall halfway. The company itself emphasizes that it will focus more on high-growth industries and strengthen exposure through acquisitions, which is both an opportunity and a sign that the transformation is still in progress.

The third category is M&A and capital-allocation risk. Trelleborg's acquisitions are not gambling-style mega deals, which is to its credit; but the continuous bolt-on acquisitions and capacity expansion since 2022 have indeed taken ROCE down from 15.9% in 2022 to 12.1% in 2025. If ROCE still fails to return to the target range over the next three years, the quality premium the market grants today could compress.

The fourth category is cycle, tariff, currency, and supply-chain risk. Among the short-term risks the company discloses, it states clearly that direct tariff impact is limited because its business is closer to local production for local markets; but supply-chain disruption, rising raw-material costs, and broader trade barriers could still erode profit and demand. Organic growth was decent in Q1 2026, but sales were still dragged 9% by currency translation. This shows that the gap between "real operations" and "reported figures" will continue to be affected by currency noise in the coming years.

The fifth category is valuation risk. This is what I consider the most realistic risk at present. What you buy today is not a bad company, but it is not a cheap company either. A high-quality industrial can stay expensive throughout a period of good conditions, stable orders, and low rates; but once margins decline or M&A returns fall short, the 23-25x clean-earnings multiple the market grants it may not hold. At that point, even if the business itself has not "broken," investors may still endure mediocre returns on capital for a fairly long time.

If I were to write the strongest argument for the other side, I would write it this way: Trelleborg's "better company" story may already be largely reflected in the share price. After divesting the tire and printing businesses, the financials look prettier; Sealing and Medical have high margins and good cash flow; and buybacks and cancellations make per-share metrics more attractive. But looking one layer deeper, ROCE has not caught up, Medical's return on capital is very low, the group is still exposed to the industrial and automotive cycles, and the current price asks investors to believe that management can keep acquiring successfully, keep sustaining high margins, and that the market will keep granting a high multiple over the long run. The moment one link in this chain fails, returns will fall clearly short of imagination.

Which facts would make me admit I was wrong? If any of the following appears in the future, I would re-examine or even overturn the "high-quality but slightly expensive" judgment: First, ROCE (excluding comparison items) returning above 15% over the long run and holding stably, which would mean I underestimated its return on incremental capital and the company should command a higher valuation; Second, Medical Solutions' ROCE recovering meaningfully into double digits, which would mean the current concern may be excessive; Third, free cash flow running clearly above the 2025-2026 level for several consecutive years, and not achieved by cutting necessary capex, in which case Owner Earnings should be revised up. Conversely, if cash conversion falls below 80%, net debt/EBITDA rises above 2.5x, ROCE stays stuck around 10% over the long run, and acquisitions grow larger with worsening returns, I would downgrade it from "Watch/holdable" to a more cautious tier.

Investment Checklist

The core conclusion of this checklist is simple: the business and the financials are broadly excellent, but the price scores nothing.

Final Investment Conclusion

【Final Rating】 Watch

【One-Sentence Investment Thesis】 Trelleborg is a high-quality industrial platform that, after portfolio optimization, has solid cash flow and a sturdy balance sheet, but the current price reflects mostly quality and does not yet offer enough value.

【Core Bull Case】

• The company focuses on critical industrial functions such as sealing, vibration damping, and protection, with a business embedded in customers' critical applications, so long-term demand is not fragile.

• The 2025 EBITA margin of 18.3% set a record high, and the Q1 2026 trailing-12-month cash conversion rate of 95% shows that both operating quality and cash-flow quality are strong.

• Net debt/EBITDA is only 1.0x-1.1x, making the balance sheet very safe and giving the company room to ride through the cycle and keep optimizing the portfolio.

• Capital allocation is broadly rational: divesting low-quality assets, doing small bolt-on acquisitions, and continually paying dividends and repurchasing and cancelling shares.

• The free-cash-flow performance in 2020 and 2023-2025 shows it is not a company propping up its valuation with "accounting profit."

【Core Bear Case】

• The current valuation of about 25x TTM profit, around 26x free cash flow, and 26-28x conservative Owner Earnings leaves an insufficient margin of safety.

• Despite high margins, ROCE is still only around 12%, below the company's long-term target of >15%.

• Medical Solutions has a high margin but ROCE of only 5.1%, indicating that returns on new acquisitions and new capacity remain to be verified.

• The business still carries exposure to automotive, industrial capex, project delivery, and currency swings; it is not a fully cycle-proof asset.

• The valuation already needs to lean on the optimistic scenario for support, rather than the conservative one.

【Key Assumptions】

• The company can convert recent acquisitions and capacity expansion into higher ROCE, rather than a heavier asset burden.

• The EBITA margin can hold around 17%-18%, rather than declining clearly.

• Free cash flow continues to hold at the SEK 3bn+ level.

• Management maintains its "small and bolt-on" acquisition style, avoiding high-premium mega deals.

• Share buybacks continue to be value-driven, rather than mechanically chasing higher prices. These are model assumptions, not factual judgments.

【Fair Buy Price】 SEK 260-310/share. The basis is to apply a further 20%-30% margin of safety between my conservative and neutral intrinsic-value ranges, which better fits the requirements of "balanced, slightly conservative" capital.

【Target Holding Period】 10 years or more. This company is not suited to judgment based on one year of profit or one quarter of orders; it is better assessed over the 5-10 year trajectory of ROCE, cash flow, and capital allocation.

【Expected Annualized Return】 Conservative scenario: 2%-4%; neutral scenario: 6%-8%; optimistic scenario: 9%-11%. This is not a market-consensus forecast but an estimate based on current valuation, dividend yield, long-term growth, and exit-multiple assumptions. At the current price, it has no easy assurance of beating the index.

【Maximum Loss Risk】 If margins decline over the next 2-3 years, ROCE does not rise, and the market compresses the valuation from 23-25x to 16-18x, while you happen to have bought near SEK 400, then even if the business has not "broken," the share price could see a medium-term drawdown of 25%-40%. The truly extreme permanent-capital-loss scenario is a large M&A misstep compounded by a cyclical downturn and deteriorating cash flow.

【Tracking Metrics】

• Group ROCE (especially excluding comparison items)

• Medical Solutions' ROCE

• Whether the group EBITA margin holds above 17%

• Operating cash flow and free cash flow

• Whether the cash conversion rate stays around 90% over the long run

• Net debt/EBITDA

• M&A size, consideration, and post-acquisition margins/returns over the following 2-3 years

• Share buyback prices and amounts

• Order/demand direction across the three major end markets of automotive, aerospace, and medical

• The translation impact of currency on sales and profit

【Signals That Trigger Reassessment】

• ROCE staying in the 10%-12% range for two consecutive years with no sign of improvement

• Cash conversion falling clearly below 80%

• Net debt/EBITDA rising above 2.5x

• The appearance of a clearly high-premium mega deal

• Growth slowing and margins declining in high-quality businesses such as medical and aerospace

• Buybacks continuing but no longer being cancelled, or executed at large scale when clearly overvalued

• Management starting to use more "adjusted" figures to play down a real decline in returns

【Final Recommendation】 If you currently have no position, I would not advise rushing to buy just because "this is a good company"; a good company does not equal a good entry point. If you already have a position with a relatively low cost basis, then I lean toward viewing it as a high-quality industrial worth continuing to hold, while monitoring ROCE and M&A returns closely. For a long-term, conservative investor who emphasizes margin of safety, the most level-headed action is not to dismiss Trelleborg, but to acknowledge that it is worth owning, but not worth owning heavily at today's price.

Open Questions and Limitations: This research has prioritized the company's latest annual/quarterly reports, IR pages, and authoritative market data, but because the web interface does not fully expand some PDFs/tables, I still recommend that you re-verify the inventory, receivables, and payables turnover detail for the past 5-10 years, as well as the latest precise shareholdings of directors and executives against the original annual-report tables or the official key-figures Excel before formally taking a position; in addition, the current share price shows slight delay differences across public sources, so I have treated it uniformly as "about SEK 398-400" in the valuation judgment.

This report is based on public information and does not constitute investment advice. Markets carry risk; invest with caution.